Session Information
Date: Wednesday, June 7, 2017
Session Title: Parkinson's Disease: Genetics
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: Study the expression of OX40 gene and its serum levels could be measured to predict and confirm diagnosis of Parkinson’s disease and help develop new treatment and prevention approaches through suppression of this interaction.
Background: Parkinson’s disease is a common neurodegenerative disease that mainly affects central nervous system (CNS) and consequently motor system. Inflammation of immune system and CNS has been known as an important predisposing factor for Parkinson’s disease. OX40 protein (CD134) is from family of tumor necrosis receptors that acts on T cells surface. Increased expression of this protein has been known as a factor for increase in inflammation and initiation of NF-kappa B signaling pathway in different diseases. This study investigates OX40 gene expression in mRNA and serum levels.
Methods: Twenty people with Parkinson’s disease and 20 healthy people, as controls, were enrolled in the study. Measurement of OX40 gene expression was conducted by real-time PCR and serum protein level measured by enzyme-linked immunosorbent assay.
Results: The mean expression rate of OX40 gene in the patients increased compared to the controls yet insignificantly (p>0.05). The mean serum concentration of OX40 protein increased in the patients yet insignificantly compared to the controls (p>0.05).
Conclusions: The expression of this protein could be measured to predict and confirm diagnosis of Parkinson’s disease and help develop new treatment and prevention approaches through suppression of this interaction. However, additional clinical, cellular, and interventional studies should be conducted to confirm the treatment approaches.
References: 1. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nature clinical practice Neurology. 2006; 2(3):136-46.
2. Xiao X, Shi X, Fan Y, Zhao P, Minze L, Ghobrial R, et al. OX40 signaling activates epigenetic mechanisms to repress Th17 cells and Th17-related autoimmune diseases (LYM5P. 708). The Journal of Immunology. 2015; 194(1 Supplement):134.13-.13.
To cite this abstract in AMA style:
F. Alsahebfosoul, A. SeyedJoodaki, N. Eskandari, V. Shaygannejad, M. Salehi, M. Kazemi, M.T. Kardi, O. Mirmossayeb. Expression of OX40 and OX40 serum level in patients with Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/expression-of-ox40-and-ox40-serum-level-in-patients-with-parkinsons-disease/. Accessed June 15, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/expression-of-ox40-and-ox40-serum-level-in-patients-with-parkinsons-disease/